ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2011

Osseous Sarcoidosis: Clinical Presentation, Treatment, and Outcomes. Experience From a Large Tertiary Care Academic Hospital

Jeffrey A. Sparks1, Jakob I. McSparron2, Christopher H. Fanta2 and Jonathan S. Coblyn3, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Bone and sarcoidosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by the formation of non-caseating granulomas. Osseous involvement in sarcoidosis is a rare manifestation and has infrequently been reported. The distribution of lesions, clinical presentation, treatment strategies, and outcomes of patients with osseous sarcoidosis are unclear. We have reviewed our experience with osseous sarcoidosis to better characterize these clinical features.

Methods: Potential cases of osseous sarcoidosis seen at a large tertiary care academic hospital by the Division of Rheumatology, Immunology and Allergy and the Division of Pulmonary and Critical Care Medicine were identified through directed inquiry and electronic health record queries. Cases were defined as having pathologic evidence of non-caseating granulomas on bone biopsy or evidence of osseous lesions on imaging attributable to sarcoidosis by the radiologist, treating clinician, and reviewer. Characteristics of the clinical presentation, treatment, and outcomes were obtained from thorough medical record review.

Results: We identified 19 cases of osseous sarcoidosis (9 with biopsy-proven disease and 10 with diagnosis based on imaging and clinical presentation). Osseous lesions were detected by imaging during the initial presentation for sarcoidosis in 11 of 19 cases (58%). In those who had a prior established diagnosis of sarcoidosis, the mean duration of sarcoidosis before osseous detection by imaging was 4.8 years. The mean duration between detection of lesions on imaging and definitive clinical diagnosis in those who had a bone biopsy was 344 days. Other systemic features of sarcoidosis were present in 18 out of 19 cases (95%). Hilar lymphadenopathy was present in most cases (16 out of 19, 84%). Symptoms were present in 10 out of 19 cases (53%) and consisted mostly of low back pain, arthralgias/arthritis, and soft tissue swelling.  Lesions were detected by magnetic resonance imaging (13 cases) and positron emission tomography (8 cases). All patients had more than one bone involved. Most patients (89%) had axial involvement, primarily in the pelvis and lumbar spine, and required no specific treatment if lesions were discovered incidentally. A minority of cases (9/19, 47%) were treated specifically for osseous sarcoidosis, mostly with prednisone and hydroxychloroquine. Two cases required multiple medications, including anti-tumor necrosis factor therapy, for refractory symptomatic osseous sarcoidosis. At last follow-up, 16 out of 19 (84%) patients were asymptomatic from osseous lesions.

Conclusion: We have identified the largest series of osseous sarcoidosis and characterized its clinical presentation, treatment, and outcomes. Patients with osseous sarcoidosis had multiple bones affected and generally had other systemic manifestations of sarcoidosis. A minority of patients required treatment of their osseous sarcoidosis for relief of symptoms and most patients were symptom-free at last follow-up.


Disclosure:

J. A. Sparks,
None;

J. I. McSparron,
None;

C. H. Fanta,

UpToDate and McGraw-Hill,

7;

J. S. Coblyn,

CVS,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osseous-sarcoidosis-clinical-presentation-treatment-and-outcomes-experience-from-a-large-tertiary-care-academic-hospital/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology